Pharmaceuticals, Biotechnology and Life Sciences
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.
Amgen on Tuesday got clearance from the European Commission (EC) for a new single-dose delivery option for its Repatha cardiovascular drug.
A newly formed biopharmaceutical company based in San Francisco, USA, has ensured funds for unlocking research of the therapeutic potential of Wnt signaling, a key for stem-cell maintenance and tissue regeneration.
Amgen co-founder Dr. Joseph Rubinfeld, who was an independet director of Amarantus BioScience Holdings has died.
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
Amgen has been given green light in the USA for its Parsabiv, the cure for chronic kidney disease patients on hemodialysis to treat secondary hyperparathyroidism (HPT).
Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…